Summary
Investigate the inhibitor development rate of Human cl rhFVIII in previously untreated patients with severe Hemophilia A.
Conditions
Severe Hemophilia A
Recruitment Status
Completed
Eligibility Criteria
Inclusion Criteria:
Male patients
Severe Hemophilia A (FVIII:C <1%)
No previous treatment with FVIII concentrates or other blood products containing FVIII
Exclusion Criteria:
Diagnosis with a coagulation disorder other than Hemophilia A
Severe liver or kidney disease
Concomitant treatment with any systemic immunosuppressive drug
Intervention
Intervention Type
Intervention Name
Biological
Human cl rhFVIII
Phase
Phase 3
Gender
Male
Min Age
N/A
Max Age
N/A
Download Date
January 19, 2021
Principal Investigator
N/A
Primary Contact Information
For more information on this trial, visit clinicaltrials.gov.
Contact
For more information and to contact the study team:
Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients
NCT01712438